Internal Medicine, Rheumatology · Miami, FL
NPI
1184715435
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
8500 SW 92nd St Ste 208b
Miami, FL, 33156
Phone (305) 661-0169
Groups this clinician bills Medicare through
Medicare paid, 2024
$7,488
66 services
Medicare patients, 2024
29
Average age 75
Drug cost, 2024
$1.2M
999 prescriptions
Company payments, 2025
$1,114
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rawan H Jumean was code 99214 (office e&m - established), 44 times for 21 patients. In total Rawan H Jumean billed 66 services in 6 codes, and Medicare paid $7,488.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-06-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 44 | 21 | $104.62 | $4,603 |
| 99205 Office E&M - New | Office | 12 | 12 | $186.63 | $2,240 |
By year: 2022 $7,195 for 68 services; 2023 $8,101 for 74 services; 2024 $7,488 for 66 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rawan H Jumean prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 176 prescriptions and refills. In total Rawan H Jumean wrote 999 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 176 | 277 | 34 | $3,810 |
| Methotrexate Methotrexate Sodium | 148 | 250 | 34 | $2,023 |
| Rasuvo Methotrexate/Pf | 136 | 143 | 18 | $80K |
| Folic Acid Generic | 115 | 215 | 29 | $398 |
| Prednisone Generic | 54 | 62 | 18 | $154 |
| Allopurinol Generic | 46 | 89 | 11 | $432 |
| Alendronate Sodium Generic | 40 | 70 | 12 | $229 |
| Prolia Denosumab | 30 | 180 | 20 | $53K |
| Tymlos Abaloparatide | 22 | 22 | Under 11 | $62K |
| Amlodipine Besylate Generic | 18 | 42 | Under 11 | $68.7 |
| Sulfasalazine Generic | 16 | 30 | Under 11 | $205 |
| Humira(Cf) Pen Adalimumab | 14 | 14 | Under 11 | $207K |
| Actemra Actpen Tocilizumab | 14 | 14 | Under 11 | $75K |
| Evenity (2 Syringes) Romosozumab-Aqqg | 13 | 13 | Under 11 | $32K |
| Forteo Teriparatide | 13 | 13 | Under 11 | $51K |
Brand drugs: 334 claims; generic drugs: 654 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rawan H Jumean $1,114 ($1,114 in general payments such as food, travel and fees) from 11 companies. The largest payer was Radius Health, Inc. with $198.
| Company | Payments | Amount |
|---|---|---|
| Radius Health, Inc. | 5 | $198 |
| Abbvie Inc. ABBV | 8 | $184 |
| Amgen Inc. AMGN | 9 | $179 |
| Novartis Pharmaceuticals Corporation NVS | 9 | $176 |
| Mallinckrodt Hospital Products Inc. | 4 | $106 |
| GlaxoSmithKline, LLC. GSK | 4 | $87.26 |
| Alvogen Inc | 2 | $58.5 |
| UCB, Inc. UCB.BR | 2 | $43.54 |
| ANI Pharmaceuticals, Inc. ANIP | 1 | $34.14 |
| Genzyme Corporation SNY | 1 | $26.86 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.